(114 days)
No reference devices were used in this submission.
No
The device description and performance testing focus on the mechanical and material properties of a delivery system for catheters, with no mention of AI or ML capabilities.
No
The device is described as providing a "pathway through which devices are introduced" and a "conduit to deliver diagnostic and therapeutic catheters," indicating it is an accessory for other devices rather than a therapeutic device itself.
No
The device is a delivery system intended to provide a pathway for other devices, including diagnostic and therapeutic catheters. It does not, itself, perform diagnostic functions. While it can deliver diagnostic catheters, the system itself is not diagnostic.
No
The device description explicitly lists physical components (sheath, dilators, guidewire) and the performance studies detail testing on these physical components (tensile strength, kink resistance, etc.), indicating it is a hardware device.
Based on the provided information, the Ventrax™ Delivery System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use clearly states that the device is "intended to provide a pathway through which devices are introduced within the chambers and coronary vasculature of the heart." This describes a device used in vivo (within the body) for delivering other devices.
- Device Description: The description details components like a sheath, dilators, and a guidewire, all designed to facilitate access and delivery within the heart.
- Lack of IVD Characteristics: There is no mention of the device being used to examine specimens derived from the human body (like blood, tissue, etc.) to provide information for diagnosis, monitoring, or compatibility testing. IVDs typically involve reagents, analyzers, or test kits used on biological samples.
Therefore, the Ventrax™ Delivery System is a medical device used for in vivo procedures, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Ventrax Delivery System is intended to provide a pathway through which devices are introduced within the chambers and coronary vasculature of the heart.
Product codes (comma separated list FDA assigned to the subject device)
DOY
Device Description
The Ventrax™ Delivery System is designed to provide a conduit to deliver diagnostic and therapeutic catheters to specific heart chambers and locations. It provides support for positioning and maintaining the position of catheters at specific locations in the heart. The sheath may be used for percutaneous entry. The system consists of four components: a sheath, a pigtail dilator, a straight dilator and a J-tipped Amplatz guidewire.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
chambers and coronary vasculature of the heart.
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
A battery of tests was performed based upon the risk assessment and requirements of the following internationally recognized standards and guidance documents pertaining to the device performance, as well as biocompatibility, sterilization, and labeling standards and guidance. Conformity to these standards demonstrates that the proposed subject device meets the acceptance criteria established by the standards as they apply to the device safety and effectiveness.
Biocompatibility Testing: The biocompatibility evaluation for the Ventrax Delivery System was conducted in accordance with the FDA guidance document: Use of International Standard ISO-10993-1, "Biological Evaluation of Medical Devices Part 1: Evaluation and Testing Within a Risk Management Process" and International Standard ISO 10993-1 "Biological Evaluation of Medical Devices - Part 1: Evaluation and Testing Within a Risk Management Process". The tests included: Cytotoxicity, Sensitization, Irritation, Acute Systemic Toxicity, Pyrogenicity, Genotoxicity, Hemolysis, Thrombogenicity, Complement Activation. The Ventrax Delivery System met the biocompatibility requirements for externally communicating device with circulating blood contact for a limited (
§ 870.1250 Percutaneous catheter.
(a)
Identification. A percutaneous catheter is a device that is introduced into a vein or artery through the skin using a dilator and a sheath (introducer) or guide wire.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo features the letters 'FDA' in a blue square, followed by the words 'U.S. FOOD & DRUG' and 'ADMINISTRATION' in blue text.
January 15, 2025
Merit Medical Systems, Inc. Jenny Soderquist Regulatory Affairs Specialist II 1600 West Merit Parkway South Jordan, Utah 84095
Re: K242873
Trade/Device Name: Ventrax™ Delivery System Regulation Number: 21 CFR 870.1250 Regulation Name: Percutaneous Catheter Regulatory Class: Class II Product Code: DOY Dated: September 20, 2024 Received: September 23, 2024
Dear Jenny Soderquist:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-device-advicecomprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatory
2
assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Image /page/2/Picture/2 description: The image shows the signature of Alexandra K. Manaras. The signature is written in a simple, clear font. The word 'Sincerely' is written above the signature. The letters '-S' are written after the last name.
For Kalkidan A. Molla Acting Assistant Director DHT2B: Division of Circulatory Support, Structural and Vascular Devices OHT2: Office of Cardiovascular Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
3
Indications for Use
510(k) Number (if known) K242873
Device Name Ventrax Delivery System
Indications for Use (Describe)
The Ventrax Delivery System is intended to provide a pathway through which devices are introduced within the chambers and coronary vasculature of the heart.
| Type of Use (Select one or both, as applicable) |
|---|
| ------------------------------------------------- |
X Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
Ventrax Delivery System
| General
Provisions | Submitter Name:
Address:
Telephone Number:
Fax Number:
Contact Person:
Date Prepared:
Registration Number: | Merit Medical Systems, Inc.
1600 West Merit Parkway
South Jordan, UT 84095
(801) 208-4579
(801) 208-3365
Jenny Soderquist
December 16, 2024
1721504 |
|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Subject Device | Trade Name:
Common/Usual Name:
Classification Name:
Regulatory Class:
Product Code:
21 CFR §:
Review Panel: | Ventrax™ Delivery System
Percutaneous catheter
Catheter, Percutaneous
II
DQY
870.1250
Cardiovascular |
| Predicate
Device | Trade Name:
Classification Name:
Premarket Notification:
Manufacturer: | Ventrax™ Delivery System
Catheter, Percutaneous
K231246
Merit Medical Systems, Inc. |
| Reference
Device | No reference devices were used in this submission. | |
| | The Ventrax™ Delivery System is designed to provide a conduit to
deliver diagnostic and therapeutic catheters to specific heart chambers
and locations. It provides support for positioning and maintaining the
position of catheters at specific locations in the heart. The sheath may
be used for percutaneous entry. The system consists of four
components: a sheath, a pigtail dilator, a straight dilator and a J-tipped
Amplatz guidewire. | |
| | VENTRAX™ DELIVERY SYSTEM COMPONENTS | |
| Device
Description | A. 8.5F Guiding Sheath Introducer: provides a conduit to deliver
diagnostic and therapeutic catheters to specific heart chambers and
locations. The sheath has an integrated valve to restrict blood loss, and
a sideport for flushing and withdrawing blood.
B. Mating Pigtail Dilator: designed to conform to the sheath introducer
inner diameter, has a tapered tip, has a pigtail at the distal end to assist
aortic valve crossing, has an integrated valve to restrict blood loss, and
has a sideport for flushing.
C. Mating Straight Dilator: designed to conform to the sheath introducer
inner diameter and has a tapered tip. Usage of this straight dilator is
optional. This straight dilator is intended to be used only when access is
unsuccessful after using the mating pigtail dilator.
D. 0.035" X 220cm J-tipped Amplatz guidewire: provide path for sheath
and dilator advancement. | |
| Indications for Use | The Ventrax™ Delivery System is intended to provide a pathway through which devices are introduced within the chambers and coronary vasculature of the heart.
There is no change in the Indications for Use Statement from the predicate to the subject device. | |
| Comparison to Predicate Device | The subject device and predicate device are similar in design and technological characteristics and are substantially equivalent. The basis of comparison between them is based on the following:
Same Clinical Use Same Indications for Use Same Basic Design Same fundamental technology/principal of operation Same Sterilization Method Same intended use The following technological differences exist between the subject device and the predicate device:
Slight Packaging Difference Different (similar) material types that meet ISO 10993-1 Similar Labeling The labeling, packaging and material differences are considered technological differences but do not raise different questions of safety or efficacy compared to the predicate. | |
| Performance Data | A battery of tests was performed based upon the risk assessment and requirements of the following internationally recognized standards and guidance documents pertaining to the device performance, as well as biocompatibility, sterilization, and labeling standards and guidance. Conformity to these standards demonstrates that the proposed subject device meets the acceptance criteria established by the standards as they apply to the device safety and effectiveness.
ISO 13485 – Quality management systems - Requirements for regulatory purposes ISO 14971 – Application of Risk Management to Medical Devices ISO 11070 – Sterile Single-Use Intravascular Introducers, Dilators and Guidewires ISO 80369-7 – Connectors for Intravascular or Hypodermic Applications ISO 80369-20 – Common Test Methods IEC 62366-1 - Medical Devices - Part 1: Application of Usability Engineering to Medical Devices ISO 10993-1 - Biological Evaluation of Medical Devices -- Part 1: Evaluation and Testing Within A Risk Management Process ISO 10993-3 - Biological Evaluation of Medical Devices - Part 3: Tests for Genotoxicity, Carcinogenicity and Reproductive Toxicity | |
510(k) Summary: K242873
5
6
- ISO 10993-4 Biological Evaluation of Medical Devices Part 4: . Selection of tests for Interactions with blood
- ISO 10993-5 Biological Evaluation of Medical Devices Part 5: ● Tests for In Vitro Cytotoxicity
- ISO 10993-10 Biological Evaluation of Medical Devices Part ● 10: Tests for Irritation and Skin Sensitization
- ISO 10993-11 Biological Evaluation of Medical Devices Part ● 11: Tests for Systemic Toxicity
- . ISO 10993-12 - Biological Evaluation of Medical Devices - Part 12: Sample Preparation and Reference Materials
- AAMI ST72 Bacterial Endotoxins-test Methods, Routine . Monitoring, And Alternatives To Batch Testing
- ISO 11135 Sterilization of Health-care Products Ethylene ● Oxide - Requirements for The Development, Validation and Routine Control of a Sterilization Process For Medical Devices
- . ISO 10993-7 - Biological Evaluation of Medical Devices - Part 7: Ethylene Oxide Sterilization Residuals
- . AAMI TIR 28 - Product Adoption and Process Equivalence for Ethylene Oxide Sterilization
- ASTM D999-08 Standard Test Methods for Vibration Testing . of Shipping Containers
- ASTM D5265-23 Standard test method for bridge impact ● testing
- ASTM F 2096-11 Standard Test Method for Detecting Gross . Leaks in Packaging by Internal Pressurization (bubble Test)
- . ASTM D4169 - Standard Practice for Performance Testing of Shipping Containers and Systems
- ISO 2233 Packaging Complete, Filled Transport Packages ● and Unit Loads - Conditioning for Testing.
- . AAMI ISO 11607 - Packaging for Terminally Sterilized Medical Devices Part 1: Requirements for Materials, Sterile Barrier Systems and Packaging Systems
- ASTM F1929 Standard Test Method for Detecting Seal Leaks . in Porous Medical Packaging By Dye Penetration
- ASTM F 88/F88M Standard Test Method for Seal Strength of ● Flexible Barrier Materials
- ASTM F 1980 Standard Guide for Accelerated Aging of Sterile ● Barrier Systems for Medical Devices
The following performance data were provided in support of the substantial equivalence determination.
Biocompatibility Testing
The biocompatibility evaluation for the Ventrax Delivery System was conducted in accordance with the FDA guidance document: Use of International Standard ISO-10993-1, "Biological Evaluation of Medical Devices Part 1: Evaluation and Testing Within a Risk Management Process" and International Standard ISO 10993-1 "Biological Evaluation of Medical Devices - Part 1: Evaluation and Testing Within a Risk Management Process".
- Cytotoxicity
- . Sensitization
7
- Irritation ●
- Acute Systemic Toxicity ●
- Pyrogenicity ●
- Genotoxicity ●
- Hemolysis ●
- Thrombogenicity ●
- Complement Activation ●
The Ventrax Delivery System met the biocompatibility requirements for externally communicating device with circulating blood contact for a limited (